布地奈德和孟鲁司特治疗儿童轻度持续性哮喘的随机对照研究  

Randomized Controlled Study of Children with Mild Persistent Asthma Treated with Budesonide and Montelukast

作　　者：廖述霞[1] 谢冬梅[2] 邓建军[3] 

机构地区：[1]四川省成都市新都区中医医院儿科,610500 [2]成都市新都区妇幼保健院儿科 [3]四川大学华西第二医院小儿感染科

出　　处：《临床合理用药杂志》2014年第6期37-38,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 对比布地奈德和孟鲁司特治疗儿童轻度持续性哮喘的临床疗效,优化儿童轻度持续性哮喘的最佳治疗方案.方法 选择2010-2012年符合入组标准的70例轻度持续性哮喘患儿,按随机数字表法分为Ⅰ组35例和Ⅱ组35例,Ⅰ组吸入布地奈德治疗,200μg/次,2次/d,早晚吸入.Ⅱ组口服孟鲁司特,＜5岁4mg每晚,5～12岁5mg每晚.两组均治疗12周.治疗前后进行患儿日间、夜间症状评分,进行诱导痰嗜酸性粒细胞计数（EOS）,检测肺功能指标第1秒用力呼吸容积（FEV1）,记录患者治疗期间复发情况.结果 Ⅰ组和Ⅱ组治疗后日间、夜间症状评分均较治疗前降低,差异有统计学意义（P＜0.05）,Ⅰ组治疗后日间、夜间症状评分低于Ⅱ组,差异有统计学意义（P＜0.05）;Ⅰ组治疗后FEV1较治疗前提高,差异有统计学意义（P＜0.05）,EOS较治疗前降低,差异有统计学意义（P＜0.05）,Ⅱ组治疗前后FEV1、EOS差异无统计学意义（P＞0.05）;Ⅰ组治疗期间复发次数少于Ⅱ组,差异有统计学意义（P＜0.05）.结论 布地奈德在改善轻度持续性哮喘肺功能及减轻气道炎症的效果明显优于孟鲁司特,能更有效缓解患者症状,可作为首选治疗方案.Objective To compare the effect of budesonide and montelukast in the treatment of children with mild persistent asthma, to optimize the best treatment method. Methods 70 children with mild persistent asthma met inclusion cri- teria from 2010 to 2012 were randomly divided into I group and II group, 35 cases in each group. I group were treated with in- haled budesonide （200ug/time）, taken at in the morning and evening, The children of II group, which were less than 5 years old, were treated with montelukast （4mg） in every night, The children of II group, which were 5 - 12 years old, were trea- ted with montelukast （5mg） in every night. Both groups were treated for 12 weeks, symptom scores of daytime and nighttime were judged before and after treatment. Inducing sputum eosinophil count （ EOS）, detecting lung function FEV1 , the situation of relapse during treatment was obtained. Results Symptom scores after treatment of daytime and nighttime were lower than be- fore in the two groups, and the difference was statistical signficance （P 〈 0. 05） . Symptom scores after treatment of daytime and nighttime in I group were lower than I1 group, the difference was statistical signficance （P 〈0. 05） ; FEVl of I group after treatment was higher than before, the difference was statistical signficance （P 〈0. 05）, EOS was lower than before, the differ- ence was statistical signficance （P 〈0. 05）, FEV~ and EOS of II group before and after treatment, the difference was not sta- tistical signficance （P 〉 0. 05） ; The recurrent during the treatment of I group was lesser than I1 group, the difference was statistical signiicance （P 〈 0. 05）. Conclusion Budesonide has better clinical results in improving lung function and reducing airway inflammation than montelukast in the treatment of children with mild persistent asthma. It can be more effectively relieve symptoms and can be used as the preferred treatment.

关 键 词：哮喘 儿童 布地奈德 孟鲁司特 

分 类 号：R725.6[医药卫生—儿科]